Clinical Trial Update: A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204) [Phase 2]

View source ↗

Summary

Phase 2 master protocol study evaluating SAR444245 in combination with other anticancer therapies for head and neck squamous cell carcinoma was terminated; resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• SAR444245

Snippet

Sponsor: Sanofi | Conditions: Squamous Cell Carcinoma of Head and Neck | Phase 2 | Status: TERMINATED | Results posted: 2025-09-22